HPM Partners LLC raised its stake in shares of Allergan plc (NYSE:AGN) by 180.5% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 21,984 shares of the company’s stock after buying an additional 14,146 shares during the period. HPM Partners LLC’s holdings in Allergan were worth $3,665,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Flagship Harbor Advisors LLC acquired a new stake in shares of Allergan in the second quarter valued at about $129,000. Kaizen Advisory LLC grew its position in shares of Allergan by 156.2% in the second quarter. Kaizen Advisory LLC now owns 830 shares of the company’s stock valued at $138,000 after purchasing an additional 506 shares during the last quarter. Migdal Insurance & Financial Holdings Ltd. grew its position in shares of Allergan by 3,193.3% in the second quarter. Migdal Insurance & Financial Holdings Ltd. now owns 988 shares of the company’s stock valued at $165,000 after purchasing an additional 958 shares during the last quarter. Aries Wealth Management acquired a new stake in shares of Allergan in the second quarter valued at about $202,000. Finally, Avestar Capital LLC grew its position in shares of Allergan by 46.1% in the first quarter. Avestar Capital LLC now owns 1,185 shares of the company’s stock valued at $183,000 after purchasing an additional 374 shares during the last quarter. Institutional investors own 77.38% of the company’s stock.

NYSE:AGN opened at $190.17 on Friday. Allergan plc has a 1 year low of $142.81 and a 1 year high of $210.10. The company has a debt-to-equity ratio of 0.34, a current ratio of 1.00 and a quick ratio of 0.85. The company has a market capitalization of $64.66 billion, a PE ratio of 11.63, a PEG ratio of 1.47 and a beta of 1.19.

Allergan (NYSE:AGN) last posted its earnings results on Thursday, July 26th. The company reported $4.42 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.13 by $0.29. Allergan had a negative net margin of 10.29% and a positive return on equity of 8.60%. The company had revenue of $4.10 billion during the quarter, compared to analysts’ expectations of $3.92 billion. During the same quarter in the previous year, the company posted $4.02 earnings per share. Allergan’s quarterly revenue was up 2.3% compared to the same quarter last year. As a group, sell-side analysts anticipate that Allergan plc will post 16.29 EPS for the current year.

The company also recently announced a quarterly dividend, which was paid on Monday, September 17th. Stockholders of record on Friday, August 17th were paid a $0.72 dividend. This represents a $2.88 dividend on an annualized basis and a dividend yield of 1.51%. The ex-dividend date was Thursday, August 16th. Allergan’s dividend payout ratio (DPR) is currently 17.61%.

In related news, Director Joseph H. Boccuzi acquired 900 shares of the company’s stock in a transaction that occurred on Thursday, August 30th. The stock was purchased at an average price of $190.59 per share, for a total transaction of $171,531.00. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Christopher J. Coughlin acquired 10,000 shares of the company’s stock in a transaction that occurred on Thursday, September 6th. The stock was bought at an average price of $190.64 per share, with a total value of $1,906,400.00. The disclosure for this purchase can be found here. Insiders own 0.37% of the company’s stock.

AGN has been the topic of several research analyst reports. Zacks Investment Research raised Allergan from a “hold” rating to a “buy” rating and set a $197.00 price target on the stock in a research report on Wednesday, July 11th. Raymond James reaffirmed a “buy” rating and issued a $232.00 price target (up from $211.00) on shares of Allergan in a research report on Monday, September 17th. Cantor Fitzgerald set a $180.00 price target on Allergan and gave the company a “hold” rating in a research report on Monday, June 11th. Deutsche Bank set a $210.00 target price on Allergan and gave the stock a “buy” rating in a research report on Wednesday, September 12th. Finally, Credit Suisse Group set a $213.00 target price on Allergan and gave the stock a “buy” rating in a research report on Tuesday, June 12th. Two investment analysts have rated the stock with a sell rating, six have issued a hold rating and seventeen have given a buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $211.91.

About Allergan

Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. It operates through US Specialized Therapeutics, US General Medicine, and International segments. The company offers a portfolio of products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology, and anti-infective therapeutic categories.

Recommended Story: Buyback

Institutional Ownership by Quarter for Allergan (NYSE:AGN)

Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.